2015 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
12.18.15
Catabasis Pharmaceuticals Completes Enrollment for Part A of the MoveDMDSM Trial, a Phase 1/2 Trial of CAT-1004 for the Treatment of Duchenne Muscular Dystrophy
12.17.15
Catabasis Names Deirdre Cunnane SVP, General Counsel
12.09.15
Catabasis Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial of CAT-2054 for the Treatment of Hypercholesterolemia
12.02.15
Catabasis Pharmaceuticals to Present at the Oppenheimer 26th Annual Healthcare Conference
11.19.15
Catabasis and ActiGraph Collaborate on an Observational Trial to Explore the Benefits of Daily Physiological Activity Monitoring in Patients with Duchenne Muscular Dystrophy
11.12.15
Catabasis Pharmaceuticals Reports Third Quarter 2015 Financial Results and Recent Corporate Highlights
10.27.15
Catabasis Pharmaceuticals Will Present CAT-1004, a Potential Disease-Modifying Agent in Development for the Treatment of Duchenne Muscular Dystrophy, at the Action Duchenne International Conference
10.26.15
Catabasis Pharmaceuticals to Report Third Quarter 2015 Financial Results and Recent Corporate Developments on Thursday, November 12
10.26.15
European Commission Grants Orphan Medicinal Product Designation for CAT-1004, Catabasis Pharmaceuticals’ Investigational Therapy for the Treatment of Duchenne Muscular Dystrophy
09.25.15
Catabasis Pharmaceuticals Will Present CAT-1004, a Potential Disease-Modifying Agent in Development for the Treatment of Duchenne Muscular Dystrophy, at the World Muscle Society Congress
09.14.15
Catabasis Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CAT-1004 for the Potential Treatment of Duchenne Muscular Dystrophy
09.02.15
Catabasis Pharmaceuticals to Participate in the Citi 10th Annual Biotech Conference and Present at the NewsMakers in the Biotech Industry Conference
08.13.15
Catabasis Pharmaceuticals Announces Positive Top-line Phase 1 Data for Hypercholesterolemia Product Candidate CAT-2054
08.13.15
Catabasis Pharmaceuticals Reports Second Quarter 2015 Financial Results and Recent Corporate Highlights
08.11.15
Catabasis Pharmaceuticals to Present at the American Chemical Society National Conference
08.04.15
Catabasis Pharmaceuticals to Present at the Wedbush PacGrow Healthcare Conference
07.28.15
Catabasis Pharmaceuticals Will Present the CAT-2000 Program of SREBP Modulators for Hyperlipidemias at the Kern Lipid Conference
07.27.15
Catabasis Pharmaceuticals and UT Southwestern Medical Center Enter into a Sponsored Research Agreement for CAT-2000 Series in Serious Lipid Disorders
07.06.15
Catabasis Pharmaceuticals Receives FDA Fast Track Designation for CAT-1004 for the Treatment of Duchenne Muscular Dystrophy
06.30.15
Catabasis Pharmaceuticals Announces Closing of Initial Public Offering
06.25.15
Catabasis Pharmaceuticals Announces Pricing of Initial Public Offering
06.17.15
Catabasis Pharmaceuticals Initiates MoveDMD, a Phase 1/2 Trial of CAT-1004 for the Treatment of Duchenne Muscular Dystrophy
06.12.15
Catabasis Pharmaceuticals to Present the Design of MoveDMD, a Phase 1/2 Trial for its Product Candidate CAT-1004 for the Treatment of Duchenne Muscular Dystrophy, at Parent Project Muscular Dystrophy’s Annual Connect Conference
06.09.15
Catabasis Pharmaceuticals to Present Data for Hypercholesterolemia Product Candidate, CAT-2054, at the National Lipid Association Scientific Sessions
06.04.15
Catabasis Pharmaceuticals Announces Preliminary Phase 1 Data for Hypercholesterolemia Product Candidate CAT-2054
05.20.15
Catabasis Pharmaceuticals to Present Data for Hypercholesterolemia Product Candidate, CAT-2054, at the 17th International Symposium on Atherosclerosis
05.08.15
Catabasis Pharmaceuticals Invited to Present in a Webinar Hosted by Parent Project Muscular Dystrophy
04.24.15
Catabasis Names Ted Hibben SVP, Corporate Development
03.24.15
Catabasis Pharmaceuticals to Present at International Ataxia Research Conference
03.10.15
Catabasis Pharmaceuticals to Present at Muscular Dystrophy Association Scientific Conference
02.06.15
Catabasis Names Rick Modi Chief Business Officer
The documents contained in (or directly accessible from) this website include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions. There are a number of important factors that could cause Catabasis’ actual results to differ materially from those indicated by such forward-looking statements, including factors identified in the company’s most recent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was first made.